SUMMARY A comparison is made between oral ornidazole in a single 1-5 g dose and tinidazole given in a 2 g dose using a double-blind technique. All the 45 women with Trichomonas vaginalis infection who were treated with ornidazole were cured. In the tinidazole-treated group 41 out of 43 women had negative cultures after treatment. Tolerance was good in both groups.
Introduction
Material and methods A study of ornidazole*, a new antiprotozoal compound for treating Trichomonas vaginalis infection, has recently been made (Skold et al., 1977) . In the study 2 g of ornidazole was given orally as a single dose. The cure rate was 100%, but eight out of the 20 women reported pronounced side effects. A high cure rate with a single dose of 2 g ornidazole has been reported recently in other clinical trials (Gaudin, 1976; Nygaard et al., 1977) . Pharmacological studies (Sk6ld et al., 1977) showed that a single dose of 2 g orally results in plasma levels of unchanged ornidazole, which are well above the minimum inhibitory concentration (MIC) for at least 36 hours after administration, with peak levels five to eight times higher than the MIC.
In a recent study (Matheson et al., 1977) administration of a single oral 1-5 g dose resulted in sufficiently high plasma concentrations to obtain a good trichomonicidal level.
The aim of the current study was to find out whether it is possible to reduce the side effects of orinidazole by giving a lower dose and at the same time maintain a satisfactory result. During 
Results
Of the 90 women admitted to the trial, one did not return for follow-up and one was regarded as having been over-diagnosed. They were both excluded from the trial; both had received tinidazole. Subjective discomforts, such as itching, irritation, and discharge, improved after two to three days in both treatment groups. Also the objective signs of infection had disappeared in most of the patients at the first follow-up visit; some other infection (due to for example, Candida albicans, Haemophilus vaginalis, or Neisseria gonorrhoeae) was usually present in those patients who still had symptoms.
Side effects were reported by six out of the 45 patients treated with ornidazole. In one case vertigo occurred one hour after taking the tablets; one woman complained of gustatory changes, and the other four of fatigue the day after treatment.
Among the patients treated with tinidazole, discomfort was reported by nine of 43 patients. Three women complained of gustatory changes, and other discomforts reported were loose stools and insomnia. All side effects were of a mild and transient character, and none required treatment.
Discussion
In this and other studies (Gaudin, 1976; Nygaard et al., 1977; Skold et al., 1977) ornidazole was proved to be a safe and easily administered drug in the treatment of T. vaginalis infection. The single dose administration is an advantage in the treatment of outpatients, as such a regimen is convenient for patients and for their partners.
In the current study the cure rate after one week was 100% for the patients treated with ornidazole, and 95% for the patients treated with tinidazole. In the ornidazole group reinfection occurred in only one of the 42 patients who attended the follow-up one month later. This finding indicates the importance of treating the partners, as well as the patients suffering from T. vaginalis infection.
Pronounced side effects occurred in earlier studies of ornidazole given as a single 2 g dose (Nygaard et al., 1977; Skold et al., 1977) . A reduction of the dose to 1 5 g reduced the side effects, and did not affect the cure rate, which was maintained at a high level. 
